INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 299 filers reported holding INTELLIA THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 1.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,921,101 | -28.7% | 124,007 | -8.1% | 0.00% | -50.0% |
| Q2 2023 | $5,499,957 | +65.1% | 134,869 | +50.9% | 0.00% | +100.0% |
| Q1 2023 | $3,330,969 | -47.4% | 89,374 | -50.8% | 0.00% | -50.0% |
| Q4 2022 | $6,336,408 | +131.2% | 181,611 | +270.9% | 0.00% | +100.0% |
| Q3 2022 | $2,741,000 | +12.8% | 48,968 | +4.4% | 0.00% | 0.0% |
| Q2 2022 | $2,429,000 | -74.9% | 46,914 | -64.8% | 0.00% | -66.7% |
| Q1 2022 | $9,679,000 | -28.9% | 133,179 | +15.7% | 0.00% | -25.0% |
| Q4 2021 | $13,615,000 | +57.5% | 115,148 | +78.7% | 0.00% | +33.3% |
| Q3 2021 | $8,647,000 | +8.1% | 64,454 | +30.4% | 0.00% | 0.0% |
| Q2 2021 | $8,001,000 | +91.3% | 49,415 | -5.2% | 0.00% | +200.0% |
| Q1 2021 | $4,182,000 | -39.0% | 52,111 | -58.6% | 0.00% | -50.0% |
| Q4 2020 | $6,852,000 | +356.5% | 125,949 | +66.7% | 0.00% | +100.0% |
| Q3 2020 | $1,501,000 | -16.7% | 75,536 | -11.9% | 0.00% | 0.0% |
| Q2 2020 | $1,802,000 | +80.4% | 85,740 | +5.0% | 0.00% | – |
| Q1 2020 | $999,000 | -40.6% | 81,669 | -28.8% | 0.00% | -100.0% |
| Q4 2019 | $1,683,000 | -44.2% | 114,734 | -49.2% | 0.00% | 0.0% |
| Q3 2019 | $3,014,000 | +19.3% | 225,714 | +46.3% | 0.00% | 0.0% |
| Q2 2019 | $2,526,000 | +4.8% | 154,323 | +9.3% | 0.00% | 0.0% |
| Q1 2019 | $2,411,000 | -13.7% | 141,136 | -31.0% | 0.00% | 0.0% |
| Q4 2018 | $2,793,000 | -29.2% | 204,601 | +48.4% | 0.00% | -50.0% |
| Q3 2018 | $3,946,000 | +19.3% | 137,899 | +14.1% | 0.00% | +100.0% |
| Q2 2018 | $3,308,000 | -18.1% | 120,905 | -36.9% | 0.00% | -50.0% |
| Q1 2018 | $4,041,000 | +154.0% | 191,616 | +131.6% | 0.00% | +100.0% |
| Q4 2017 | $1,591,000 | -8.0% | 82,738 | +18.8% | 0.00% | 0.0% |
| Q3 2017 | $1,730,000 | +73.5% | 69,624 | +11.7% | 0.00% | 0.0% |
| Q2 2017 | $997,000 | +16.1% | 62,304 | +2.2% | 0.00% | – |
| Q1 2017 | $859,000 | +472.7% | 60,935 | +432.0% | 0.00% | – |
| Q4 2016 | $150,000 | +525.0% | 11,455 | +708.4% | 0.00% | – |
| Q3 2016 | $24,000 | +14.3% | 1,417 | +41.7% | 0.00% | – |
| Q2 2016 | $21,000 | – | 1,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |